TEVA REMINDER: Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important January 5 Deadline in Class Action Filed by Firm- TEVA
December 27, 2016 09:00 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited...
Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVA
December 12, 2016 18:23 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the American Depositary...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
December 08, 2016 11:06 ET
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to...
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities Case
November 08, 2016 10:53 ET
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to file...
Agile Therapeutics Reports First Quarter 2016 Financial Results
May 09, 2016 16:10 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations through the End of 2017Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017 PRINCETON, N.J., May 09, 2016 ...
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
February 02, 2016 08:00 ET
|
AbCellera
JERUSALEM and VANCOUVER, British Columbia, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
September 29, 2015 21:10 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
Mesoblast Unveils Path to Bring Its Key Products to Market
August 25, 2014 20:27 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
Mesoblast Reports Strong Half-Year Financial Results
February 25, 2014 17:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS
October 30, 2013 18:41 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...